Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Lck Inhibitor III
CAS:<p>Lck Inhibitor III, a potent inhibitor of Lck, exhibits an IC50 value of 867 nM.</p>Fórmula:C25H30N6O4Forma y color:SolidPeso molecular:478.54K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Forma y color:SolidPeso molecular:425.44EGFR/BRAFV600E-IN-1
CAS:<p>EGFR/BRAFV600E-IN-1 inhibits EGFR (0.08 μM) & BRAFV600E (0.15 μM), affects A-549, MCF-7, Panc-1 & HT-29 (IC50: 0.79-1.3 μM).</p>Fórmula:C24H24ClN3O3Forma y color:SolidPeso molecular:437.92PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44ALK5-IN-30
CAS:<p>ALK5-IN-30 (EX-07) is a potent inhibitor of ALK with inhibitory effects on ALK5 (IC50< 10 nM) and TGFβ-R1 (IC50< 10 nM).</p>Fórmula:C24H25FN8Forma y color:SolidPeso molecular:444.51VEGFR-2-IN-27
CAS:<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Fórmula:C25H21FN4O4Forma y color:SolidPeso molecular:460.46Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Fórmula:C37H35F2N5O9SPureza:98%Forma y color:SolidPeso molecular:763.76BIIB-057
CAS:<p>BIIB-057 is a selective Syk inhibitor.</p>Fórmula:C19H23N9OPureza:98%Forma y color:SolidPeso molecular:393.45Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Fórmula:C28H23ClF3N7O2Forma y color:SolidPeso molecular:581.98Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Fórmula:C32H39N9O2Forma y color:SolidPeso molecular:581.71Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39Y 11
CAS:<p>focal adhesion kinase (FAK) inhibitor</p>Fórmula:C8H17BrN4OPureza:98%Forma y color:SolidPeso molecular:265.15EGFR-IN-46
CAS:<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Fórmula:C27H32F3N3O3Forma y color:SolidPeso molecular:503.56EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64FAK/aurora kinase-IN-1
CAS:<p>FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].</p>Fórmula:C23H24ClN7O3Forma y color:SolidPeso molecular:481.93JTV-519 free base
CAS:JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmicFórmula:C25H32N2O2SPureza:98%Forma y color:SolidPeso molecular:424.6PF-00337210
CAS:<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Fórmula:C26H27N3O5Forma y color:SolidPeso molecular:461.51GW694590A
CAS:<p>GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].</p>Fórmula:C22H19N5O4Forma y color:SolidPeso molecular:417.42VEGFR-2-IN-20
CAS:<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Fórmula:C20H20N4O3SForma y color:SolidPeso molecular:396.46FGFR2-IN-2
CAS:<p>FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.</p>Fórmula:C23H22N4OPureza:98.09%Forma y color:SolidPeso molecular:370.45EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6Depatuxizumab mafodotin
CAS:<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Forma y color:LiquidTHS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Fórmula:C11H12F3N3O3Pureza:99.89%Forma y color:SolidPeso molecular:291.23KL-1156
CAS:<p>KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.</p>Fórmula:C17H17NO4Pureza:98%Forma y color:SolidPeso molecular:299.32WDR5-IN-4
CAS:WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.Fórmula:C25H22Cl2FN5OPureza:98%Forma y color:SolidPeso molecular:498.38VEGFR-2-IN-19
CAS:<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Fórmula:C21H19N3O2Forma y color:SolidPeso molecular:345.39FM19G11
CAS:<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Fórmula:C23H17N3O8Pureza:99.70%Forma y color:SolidPeso molecular:463.4Glufanide disodium
CAS:<p>Glufanide disodium is an immunomodulator.</p>Fórmula:C16H17N3O5Na2Forma y color:SolidPeso molecular:377.3FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Fórmula:C23H26F3N7O2Forma y color:SolidPeso molecular:489.49R916562
CAS:R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.Fórmula:C26H30ClN9SPureza:98%Forma y color:SolidPeso molecular:536.09(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94AZM475271
CAS:<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Fórmula:C23H27ClN4O3Pureza:99.78%Forma y color:SolidPeso molecular:442.94TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41SB-220025 trihydrochloride
CAS:<p>SB-220025 trihydrochloride is an effective and specific human p38 mitogen-activated protein kinase inhibitor.</p>Fórmula:C18H22Cl3FN6Pureza:98%Forma y color:SolidPeso molecular:447.77WB-308
CAS:<p>WB-308 is an EGFR inhibitor that acts by decreasing NSCLC cell proliferation and colony formation and causing G2/M arrest and apoptosis.</p>Fórmula:C19H17FN2OPureza:98%Forma y color:SolidPeso molecular:308.35Tyrphostin AG 568
CAS:<p>Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.</p>Fórmula:C13H9N5O2Pureza:98%Forma y color:SolidPeso molecular:267.24Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5TX-1918
CAS:<p>TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.</p>Fórmula:C14H12O3Forma y color:SolidPeso molecular:228.24CGP60474
CAS:CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82FGFR2-IN-1
CAS:FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used to study FGFR2-associated cancers.Fórmula:C22H19N3O2Pureza:98.71%Forma y color:SolidPeso molecular:357.41KRCA-0713
CAS:<p>KRCA-0713 is a ALK inhibitor.</p>Fórmula:C26H32ClN5O3SPureza:98%Forma y color:SolidPeso molecular:530.08BGB659
CAS:<p>BGB659 is effective inhibitor of RAF.</p>Fórmula:C29H29F3N4O3Pureza:98%Forma y color:SolidPeso molecular:538.564-DAMP
CAS:<p>4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.</p>Fórmula:C21H26INO2Pureza:98%Forma y color:SolidPeso molecular:451.34BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Fórmula:C27H52BrN8O3PPureza:98%Forma y color:SolidPeso molecular:647.644Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Fórmula:C30H33N7O2Pureza:98%Forma y color:SolidPeso molecular:523.63EGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22BI1002494
CAS:<p>BI1002494 is an effective and selective Syk inhibitor.</p>Fórmula:C23H25N3O5Pureza:98%Forma y color:SolidPeso molecular:423.46BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Fórmula:C25H23N5O3Pureza:98%Forma y color:SolidPeso molecular:441.48OD36
CAS:<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Fórmula:C16H15ClN4O2Pureza:99.89%Forma y color:SolidPeso molecular:330.77J-1048
CAS:<p>J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/</p>Fórmula:C23H17FN6S2Forma y color:SolidPeso molecular:460.55JG26
CAS:JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively,Fórmula:C19H22Br2N4O6SPureza:98.79% - 99.08%Forma y color:SolidPeso molecular:594.27YLT192
CAS:<p>YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.</p>Fórmula:C21H19N3O4Pureza:98%Forma y color:SolidPeso molecular:377.39Flonoltinib
CAS:<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Fórmula:C25H34FN7OPureza:99.52%Forma y color:SolidPeso molecular:467.58DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Forma y color:SolidPeso molecular:389.45Naphazoline
CAS:<p>Naphazoline (Naphcon-a) is a sympathomimetic compound with marked alpha adrenergic activity.</p>Fórmula:C14H14N2Pureza:99.79%Forma y color:White Crystalline Powder SolidPeso molecular:210.27SJF620
CAS:<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Fórmula:C41H44N8O7Pureza:98%Forma y color:SolidPeso molecular:760.84MG-262
CAS:<p>MG-262 is a reversible proteasome inhibitor with multiple biological activities [1] [2] [3].</p>Fórmula:C25H42BN3O6Forma y color:SolidPeso molecular:491.43E-4177
CAS:<p>E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.</p>Fórmula:C24H21N3O2Pureza:98.67% - 99.57%Forma y color:SolidPeso molecular:383.44CJ-2360
CAS:<p>CJ-2360 is a potent ALK inhibitor, effective on wild-type and various mutants, with IC50 values ranging from 2.2 to 8.9 nM, also targeting 468 kinases.</p>Fórmula:C27H30FN5O2Forma y color:SolidPeso molecular:475.56MAX-40279 hydrochloride
CAS:<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Fórmula:C22H24ClFN6OSForma y color:SolidPeso molecular:474.98Con B-1
CAS:<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Fórmula:C38H52ClN7O6SForma y color:SolidPeso molecular:770.38PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56EGFR-IN-40
CAS:<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Fórmula:C23H20N6O3Forma y color:SolidPeso molecular:428.44BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.76EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Fórmula:C18H12F3N3O2Forma y color:SolidPeso molecular:359.3Derazantinib Racemate
CAS:<p>Derazantinib Racemate is an oral ATP competitive kinase inhibitor targeting FGFR1/2/3 (IC50s: 4.5/1.8/4.5 nM).</p>Fórmula:C29H29FN4OPureza:98%Forma y color:SolidPeso molecular:468.57FGFR-IN-3
CAS:<p>FGFR-IN-3: potent, oral FGFR modulator, BBB-penetrating, neuroprotective, potential in neurodegeneration study.</p>Fórmula:C18H27F2N5O2Forma y color:SolidPeso molecular:383.44EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56MAX-40279
CAS:<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Fórmula:C22H23FN6OSForma y color:SolidPeso molecular:438.52EGFR/HER2/TS-IN-1
CAS:<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Fórmula:C24H15N5O4S2Forma y color:SolidPeso molecular:501.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Fórmula:C19H14F3N3O2Forma y color:SolidPeso molecular:373.33VEGFR-2-IN-23
CAS:<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Fórmula:C22H15N5O2Forma y color:SolidPeso molecular:381.39EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Fórmula:C18H23BrN4O2Forma y color:SolidPeso molecular:407.312JS25
CAS:<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Fórmula:C29H24N4O4SForma y color:SolidPeso molecular:524.59Lck-IN-1
CAS:<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Fórmula:C14H15N5Forma y color:SolidPeso molecular:253.3CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Forma y color:SolidPeso molecular:562.54AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Fórmula:C15H12N4SForma y color:SolidPeso molecular:280.35α7 nAchR-JAK2-STAT3 agonist 1
CAS:<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Fórmula:C25H30O6Forma y color:SolidPeso molecular:426.5Mutated EGFR-IN-2
CAS:Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Fórmula:C23H23N3O3Forma y color:SolidPeso molecular:389.45BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Fórmula:C25H21Cl2N5O2Forma y color:SolidPeso molecular:494.37Luxeptinib
CAS:<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Fórmula:C25H17F4N5O2Forma y color:SolidPeso molecular:495.43Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SForma y color:SolidPeso molecular:566.07GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Forma y color:SolidPeso molecular:489.86TG53
CAS:<p>TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor.</p>Fórmula:C21H22ClN5O2Pureza:98%Forma y color:SolidPeso molecular:411.88GW837016X
CAS:<p>GW837016X, also known as NEU-391, is a potent inhibitor of protozoan parasite proliferation.</p>Fórmula:C25H20ClFN4OSForma y color:SolidPeso molecular:478.97PHA-680626
CAS:<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Fórmula:C23H26N6O2SForma y color:SolidPeso molecular:450.56Nuvenzepine
CAS:Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.Fórmula:C19H20N4O2Pureza:98%Forma y color:SolidPeso molecular:336.39FGFR-IN-9
<p>FGFR-IN-9: oral FGFR inhibitor, IC50: 17.1 nM (FGFR4 WT), 29.6 (FGFR3), 30.7 (V550L), 46.7 (FGFR2), 64.3 nM (FGFR1).</p>Fórmula:C25H28N6O3SForma y color:SolidPeso molecular:492.59EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31AP 24149
CAS:<p>AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.</p>Fórmula:C23H24N5OPForma y color:SolidPeso molecular:417.44BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52
